Yuancheng (Ryan) Lu isn’t just theorizing about aging; he’s fixing it in the lab. The 34-year-old geneticist at the Whitehead Institute has moved his groundbreaking optic nerve repair technique from mice to humans. On June 9, Life Biosciences, a startup cofounded by longevity pioneer David Sinclair, administered the treatment, known as ER-100, to a patient with glaucoma. This marks a critical transition for reprogramming technology, moving it from academic curiosity to clinical reality.
The science hinges on cellular reprogramming, a process that resets aged cells to a youthful state. While Japanese researchers identified the four-gene OSKM cocktail in 2006, Lu found a safer path. He removed Myc, the gene most likely to trigger cancer, leaving just OSK. In 2018, he used this trimmed-down version to restore sight in blinded mice. Their optic nerves regenerated, and behavioral tests confirmed they could track light again. Sinclair recalled seeing those results and texting Lu: “I see the future.”
Hype has outpaced caution in some corners. Headlines have proclaimed the “fountain of youth” is here, and tech billionaires are pouring billions into ventures like Altos Labs. But Lu remains grounded. He views his earlier work as a proof of concept rather than a universal cure. The therapy still faces toxicity issues in various cell types, and aging mechanisms differ across tissues. Lu recently identified a specific gene protecting retinas from free radical damage, highlighting the complexity of targeting age-related macular degeneration.
Lu’s personal stake drives his rigor. With a family history of blindness and a genetic predisposition to macular degeneration, he wears aviator shades not just for style but for protection. He disagrees with Sinclair’s prediction that humans will live to 200, arguing that too many biological systems fail simultaneously. Yet, he acknowledges his work shifted the Overton window. Six years ago, rejuvenation was a fringe concept. Now, it’s a clinical trial. The question isn’t if we can reverse molecular age, but how safely we can do it without turning patients into stem-cell blobs.
